AbbVie's Muted Gains Highlight 72nd-Ranked $1.34B Volume Amid Strategic Shifts

AbbVie (ABBV) closed on Sept. , , which ranked 72nd in market activity. The stock's muted performance contrasted with broader market trends, reflecting a mix of strategic developments and market positioning.

Recent corporate actions highlighted AbbVie's ongoing focus on its core therapeutic areas. The company announced a partnership expansion in oncology drug distribution, solidifying its supply chain infrastructure. Additionally, management reiterated confidence in the long-term trajectory of Humira biosimilars, emphasizing stable revenue projections amid competitive pressures.

Investor sentiment remained cautious as the company navigated regulatory timelines for a key rheumatology candidate. While no immediate approvals were announced, analysts noted the strategic value of the pipeline in maintaining market share. Share repurchase authorization updates were also mentioned, though specific figures were deferred to future disclosures.

To perform this back-test accurately I need to pin down a few practical details: Universe - Should we scan all U.S. common stocks (NYSE, NASDAQ, AMEX) every trading day, or a narrower list (e.g., S&P 1500 constituents)? Re-balancing mechanics - Do we buy the top-500 by dollar volume or by share volume? Entry price: today’s close or next day’s open? Exit price: next day’s close or open? Equal-weight each position for the day? Frictions - Do you want to include transaction costs (commissions or bid/ask impact) or assume zero cost? Data limitations - Our current back-test engine handles one ticker at a time. If you’re comfortable with an approximation, I can construct a daily “synthetic index” that represents the equal-weighted return of the top-500-volume basket and back-test that index. Otherwise we would need external code beyond the chat-based toolset. Let me know your preferences on the above so I can set up the most realistic test possible.